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Background: Peroxisome proliferator-activated receptor-γ (PPARγ) agonists, which have been used as insulin
sensitizers in diabetic patients, may improve functions of endothelial cells (ECs). We investigated the effect of PPARγ
on angiogenic activities of murine ECs and bone marrow-derived proangiogenic cells (PACs).
Methods: PACs were isolated from bone marrow of 10–12 weeks old, wild type, db/db and PPARγ heterozygous
animals. Cells were cultured on fibronectin and gelatin coated dishes in EGM-2MV medium. For in vitro stimulations,
rosiglitazone (10 μmol/L) or GW9662 (10 μmol/L) were added to 80% confluent cell cultures for 24 hours.
Angiogenic potential of PACs and ECs was tested in vitro and in vivo in wound healing assay and hind limb
ischemia model.
Results: ECs and PACs isolated from diabetic db/db mice displayed a reduced angiogenic potential in ex vivo and
in vitro assays, the effect partially rescued by incubation of cells with rosiglitazone (PPARγ activator). Correction of
diabetes by administration of rosiglitazone in vivo did not improve angiogenic potential of isolated PACs or ECs. In
a hind limb ischemia model we demonstrated that local injection of conditioned media harvested from wild type
PACs improved the blood flow restoration in db/db mice, confirming the importance of paracrine action of the
bone marrow-derived cells.
Transcriptome analysis showed an upregulation of prooxidative and proinflammatory pathways, and
downregulation of several proangiogenic genes in db/db PACs. Interestingly, db/db PACs had also a decreased
level of PPARγ and changed expression of PPARγ-regulated genes. Using normoglycemic PPARγ+/− mice we
demonstrated that reduced expression of PPARγ does not influence neovascularization either in wound healing
or in hind limb ischemia models.
Conclusions: In summary, activation of PPARγ by rosiglitazone improves angiogenic potential of diabetic ECs and
PACs, but decreased expression of PPARγ in diabetes does not impair angiogenesis.
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Peroxisome proliferator-activated receptor gamma (PPARγ)
is a ligand-dependent transcription factor of nuclear
receptor superfamily, involved in regulation of lipid me-
tabolism, insulin sensitivity, and inflammatory response
[1,2]. Synthetic PPARγ agonists (thiazolidinediones), such
as rosiglitazone (ROSI), pioglitazone, and troglitazone,
have been used for many years in patients with type 2
diabetes (T2DM) to improve insulin resistance and
ameliorate hyperglycemia [3].
Diabetes, due to hyperglycemia and insulin resistance,
is associated with poor outcomes due to endothelial dys-
function and impaired angiogenesis, followed by vascular
occlusive events, decreased vascular density in ischemic
tissues, and delayed wound healing [4,5]. Proper vascular
repair and angiogenesis depend both on mature endothe-
lial cells and endothelial progenitors [6,7]. Bone marrow-
derived endothelial progenitor cells (EPCs) were first
characterized in 1997 as a CD34+ population mobilized
into the peripheral blood in response to ischemia, cap-
able of incorporating into injured vessels and involved in
tissue revascularization [8]. In further studies a broad
spectrum of protocols for isolation or characterization of
EPCs has been used, which makes the comparison of the
results difficult. It seems, however, that cells named EPCs
are rather a heterogenous population containing mainly
monocytes with angiogenic properties [9]. They can
produce a range of growth factors including the vascular
endothelial growth factor-A (VEGF-A), stromal cell-
derived factor-1 (SDF-1), or interleukin-8 (IL-8), and this
paracrine activity is supposed to be the most important
for compensatory vascularization in ischemic tissues
[10-12]. Despite lack of standardized definition, the
analyzes have consistently indicated that the bone marrow-
derived proangiogenic cells are altered in type 2 diabetes.
Either in animal models or in human patients, diabetes
reduces number of EPCs, impairs their mobilization, and
decreases their angiogenic potential [13-18].
The deleterious effects of diabetes on mature endothe-
lium and bone marrow-derived proangiogenic cells can
be favorably modulated by PPARγ agonists. Hence, treat-
ment with rosiglitazone facilitated reendothelialization in
diabetic patients, through decreased ROS generation and
improved bioavailability of nitric oxide (NO) in endothe-
lial cells [19]. It also increased the number of circulating
EPCs and normalized their migratory activity [20].
Importantly, PPARγ agonists may improve endothelial
functions and angiogenic capacities independently of
insulin sensitizing in normoglycemic patients [21-23].
They were also shown to upregulate expression of VEGF
in rat and human vascular smooth muscle cells [24,25].
Direct proangiogenic activity of PPARγ agonists have
been described in human umbilical vein endothelial
cells (HUVECs), where expression of VEGF receptor-2(VEGFR-2) and formation of cord-like structures on
Matrigel were enhanced in response to troglitazone [26].
However, the effect of PPARγ on angiogenic activities of
endothelial cells is still not clear, as inhibition of cord-
like structure formation, decreased proliferation, and
impaired migration have also been reported in HUVECs
treated with PPARγ agonists [27,28]. Moreover, while there
are numerous papers on vascular effects of PPARγ agonist,
much less is known about potential consequences of
PPARγ deficiency or inhibition. It has been shown that
administration of PPARγ antagonist (T0070907) in preg-
nant rats led to endothelial dysfunction, reduced expression
of VEGF and increased level of plasma soluble VEGF
receptor-1 (sVEGFR-1), which acts as a VEGF scavenger
[29]. Accordingly, lack of PPARγ impaired vascular prolifer-
ation and led to vasculature defects in murine placentas,
what was a unique cause of PPARγ−/− lethality [30]. These
observations indicate that proper expression of PPARγ may
be an important issue in regulation of angiogenesis. There-
fore, we examined the effects of PPARγ activation and
PPARγ inhibition on angiogenic activities of endothelial
and bone marrow-derived proangiogenic cells (PACs) in
diabetic and normoglycemic conditions.
Materials and methods
Reagents
Endothelial cell basal medium-2 (EBM-2) with a growth
factor supplement was obtained from Lonza. MCDB-131
medium, phosphate buffered saline (PBS), Accutase and
fetal bovine serum (FBS) were from PAA Laboratories.
BS1 lectin was purchased from Vector Laboratories. DiI
labeled acetylated low density lipoproteins (DiI-AcLDL)
were from Invitrogen and QCM cell migration assay from
Chemicon. Mouse VEGF ELISA, mouse SDF-1 ELISA,
and growth factor-reduced Matrigel were obtained from
R&D Systems. Fenozol was obtained from A&A Biotech-
nology. Anti-mouse proliferating cell nuclear antigen
(PCNA) antibody was purchased from Dako. Anti-mouse
antibodies against stem cell antigen-1 (Sca-1), chemokine
receptor type-4 (CXCR4), CD45, and kinase insert domain
receptor (KDR, VEGFR-2) used for immunophenotyping
of PACs, antibodies recognizing mouse CD31 used for im-
munohistochemistry and PharmLyse were obtained from
BD Biosciences. All other reagents were purchased from
Sigma.
Cell culture
PACs were cultured as described earlier [12]. In short:
total bone marrow cells were flashed from tibias and fe-
murs of mice and centrifuged on Ficoll gradient. Cells
from the interphase were washed three times with PBS,
seeded on fibronectin (20 μg/mL) and gelatin (0.25%)
coated dishes in EGM-2MV medium (EBM-2 with growth
factor supplement) containing 10% FBS, and cultured up
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(humidified atmosphere, 21% O2, 5% CO2). In some
experiments the cells were cultured in hypoxia (2% O2, 5%
CO2 for 24 hours). Phenotype of the cultured cells was
validated by uptake of DiI-AcLDL (10 μg/mL), binding of
FITC-labeled BS1 lectin, expression of progenitor, endo-
thelial or hematopoietic marker mRNAs, and presence of
Sca-1, CXCR4, KDR and CD45 proteins.
For in vitro stimulations, rosiglitazone (10 μmol/L) or
GW9662 (10 μmol/L) were added to 80% confluent cell
cultures for 24 hours. In case of PPARγ inhibition with
GW9662 followed by stimulation with rosiglitazone the
inhibitor was added first, 30 minutes ahead.
HUVECs were cultured in MCDB-131 complete
medium, supplemented with 10% FBS endothelial cell
growth supplement (ECGS) and hydrocortizone [12].
Animals
All experiments were approved by the Local Ethical Com-
mittee for Animal Research at the Jagiellonian University.
Mice were handled according to good animal practice
in science, with a food and water access ad libitum. Wild
type and db/db mice (C57BLKS background) were
purchased from Taconic (Denmark), whereas PPARγ wild
type and heterozygous animals (C57BL/6 J background)
were kindly provided by Dr. Laszlo Nagy (University of
Debrecen). In all experiments 10–12 weeks old mice were
employed. For in vivo drug delivery mice were treated
daily for two weeks by oral gavage either with rosiglita-
zone (10 mg/kg body weight) or placebo (control WT and
db/db mice).
Migration
80% confluent PACs were detached using Accutase. Next,
10,000 cells were seeded in EBM-2 empty medium on
the top of 8-μm transwell filters and stimulated with rosi-
glitazone (10 μmol/L) and/or GW9662 (10 μmol/L,
added 30 minutes before rosiglitazone). Lower chamber
was filled with EGM-2MV medium supplemented with
10% FBS. Cells were incubated overnight under standard
culture conditions. Then, the migrated cells on the
underside of the membrane were fixed in 3% paraformal-
dehyde for 10 minutes, washed with PBS and stained
with crystal violet solution, according to vendor's proto-
col. For each sample the number of cells was calculated
as mean cell count of 10 randomly-selected microscopic
fields using Nikon Eclipse TX-100 microscope.
Tube formation on matrigel
Growth factor-reduced Matrigel was poured into a 96-well
plate (50 μL/well) and incubated at 37°C for 15 minutes.
Then 20,000 PACs were seeded to each well and stimulated
with rosiglitazone (10 μmol/L) and/or GW9662 (10 μmol/
L, added 30 minutes before rosiglitazone). Resulting tube-like structures were counted in whole well after the 16 h
incubation period using Nikon Eclipse TX-100 microscope.
Proliferation assay
PACs were seeded in chamber slides and cultured in
standard conditions until reaching a confluence of 70%.
Proliferating cells were stained with anti-mouse PCNA
antibody and PCNA-positive cells were counted using
the fluorescence microscope (Nikon Eclipse TX-100).
Flow cytometry
PACs number in the peripheral blood and in the bone
marrow was measured on the basis of analysis of
CD45−KDR+Sca-1+ population. Peripheral blood was
harvested from vena cava superior into heparinized
syringe, whereas bone marrow was flushed from tibias
and femurs. Next, red blood cells were removed with
PharmLyse buffer and, after washing, cells were incu-
bated with anti-mouse antibodies (APC-Cy7 CD45,
FITC Sca-1 and APC KDR) for 30 minutes at 4°C in
RPMI 1640 medium containing 2% FBS. Data were
collected from at least 1,000,000 events using a cyto-
fluorometer (LSR II; Becton Dickinson) and analyzed
using FACSDiva software (BD Biosciences).
ELISA
Concentrations of VEGF and SDF-1 proteins in blood
plasma and tissue lysates were measured by ELISA tests
according to vendor's protocol.
Gene expression analysis
Total RNA was isolated from PACs and from bone mar-
row (after lysis of red blood cells) with a modified guanidi-
nium isothiocyanate method. For cDNA synthesis 0.5 μg
RNA was used. Gene expression was measured by real
time PCR (StepOnePlus, Applied Biosystems) according
to the protocol: 95°C for 5 minutes followed by 40 cycles
of melting at 95°C – 30 s, annealing at 58-62°C – 60 s,
elongation at 72°C – 45 s. Primer sequences, annealing
temperatures, and length of PCR products are listed in
Additional file 1: Table S1.
Wound healing
Wound healing assay was performed as described previ-
ously [31]. Two full-thickness circular wounds (4 mm in
diameter) on each animal were created using disposable
biopsy punch. Each wound was photographed every day
and analyzed using ImageJ software.
Hind limb ischemia
Left femoral artery ligation was performed to induce
limb ischemia in WT, PPARγ deficient and db/db mice.
The superficial blood flow of the ischemic and contralat-
eral foot was analyzed by a laser Doppler flowmeter
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and in contralateral foot was calculated and used as an
index of blood flow recovery.
For cell therapy, PACs were isolated from WT mice and
cultured up to confluence in standard conditions. Then
the growth medium was changed to EBM-2 containing
0.5% FBS, which was harvested after a 24 h incubation
period to obtain PAC-conditioned medium. Conditioned
media were frozen for further use. Diabetic mice (db/db)
were subjected to femoral artery ligation and next day the
conditioned media, control media (EBM-2 with 0.5% FBS)
or PACs (250,000 cells in control medium) in a total
volume of 50 μL were injected intramuscularly into 3
sites of ischemic gastrocnemius muscle. Blood flow
measurements were performed weekly till 28th day after
injections. At the end of experiment gastrocnemius
muscles were frozen for immunohistochemical and
histochemical analyzes.
Immunohistochemical staining
Vascularization of gastrocnemius muscles was assessed
by CD31 staining of endothelial cells. For this purpose,
frozen sections of muscle (6 μm) were dried for 1 h in
room temperature and then fixed for 10 minutes in
acetone (4°C). Sections were blocked in 10% goat serum,
0.05% Tween-20, 0.1% TritonX-100 for 1 h in room
temperature, and then incubated with anti-mouse CD31
antibodies for 1.5 h. After washing, sections were
incubated with rhodamine-labeled secondary antibodies
for 30 minutes in room temperature, washed and
mounted in fluorescent mounting medium. The number
of capillaries per muscle fiber were counted from 10
random fields for each specimen using Nikon Eclipse
TX-100 microscope.
Statistical analysis
Results are expressed as mean ± SEM. In vitro experi-
ments were carried out 3–10 times. In vivo experiments
were done with 5–9 mice per group. Two tailed Student’s
t test was used for comparison of two groups, while one-
way ANOVA with Bonferroni posttest way applied for
comparison of multiple groups.
Full length description of methods is available in the
supplemental file.
Results
Characterization of bone marrow-derived PACs
Bone marrow-derived proangiogenic cells isolated
from healthy C57BL6/J (wild type, WT) mice and cul-
tured for 9–11 days under conditions promoting the
endothelial differentiation, generated a heterogeneous
population, with 80-90% of cells incorporating acLDL
and binding BS1 lectin, capable of forming the
capillary-like structures after seeding on Matrigel(Additional file 2: Figure S1A-D), which confirmed our
earlier observation [12]. Such population was 450- to
650-fold enriched in CD45−KDR+Sca-1+ cells comparing
to freshly isolated bone marrow, although their content,
even after such enrichment, did not exceed 0.5%. PACs
derived from db/db diabetic mice displayed similar
morphology or acLDL and BS1 staining and similar
level of enrichment in CD45−KDR+Sca-1+ cells (data not
shown).
Transcriptome analysis revealed that expression of
genes typical for progenitor cells (e.g. Sca-1, c-kit, CD34),
endothelial cells (e.g. KC, vascular cell adhesion molecule-
1 (VCAM-1), endoglin, von Willebrand factor (vWF), and
hematopoietic cells (e.g. CD11b, CD14) can be detected in
the heterogeneous PAC populations at the levels similar in
WT and db/db cells (data not shown). FACS immunophe-
notyping showed that vast majority of PACs expressed
CD45, a pan-hematopoietic marker, and proportion of
such cells was slightly higher in the db/db than in WTcul-
tures (85 ± 1% vs. 77 ± 1%). On the other hand, frequency
of KDR-positive cells, these expressing typical endothelial
marker, was lower in population isolated from db/db mice
(5 ± 1% vs.10 ± 2%. More than 60% of both WT and db/db
cells were positive for CXCR4 and Sca-1 markers, prefer-
entially expressed on progenitor cells (Additional file 2:
Figure S1E).
Angiogenic potential of PACs
In a set of in vitro experiments we compared angiogenic
potential of wild type and db/db PACs. Spontaneous
proliferation, measured using immunohistochemical
detection of PCNA, was similar in cells isolated from
healthy and diabetic animals (Figure 1A). All other
activities measured, namely migration (Figure 1B),
sprouting of capillaries from PACs spheroids embedded
in collagen (Figure 1C), and formation of cord-like struc-
tures on Matrigel (Figure 1D) were attenuated in db/db
cells, indicating their impaired angiogenic potential.
Similarly, angiogenic activity of mature endothelial cells
derived from aorta of db/db mice tended to be weaker, as
illustrated by the results of semiquantitative ring assay
(Figure 1E).
Since angiogenesis can be stimulated by bone marrow-
derived cells in a paracrine way, we also evaluated the
effect of conditioned media collected from the cultured
PACs on HUVEC cells seeded on Matrigel. As shown in
Figure 1F, PACs isolated from diabetic mice displayed a
weaker paracrine activity – they induced formation of
sparser capillary network by HUVEC endothelial cells
(Figure 1F).
Effect of rosiglitazone on angiogenic potential of PACs
There are discrepancies between papers describing either
proangiogenic [5,20-22,32], antiangiogenic [27,28,33-35]
Figure 1 Angiogenic potential of PACs and endothelial cells from wild type (WT) and diabetic (db/db) mice. A: Proliferation of PACs.
Immunohistochemical detection of PCNA-positive cells. B: Migration of PACs in modified Boyden chambers. C: Formation of sprouts from PACs
spheroids embedded in collagen gel, shown as a total length of sprouts per one spheroid. D: Formation of cords by PACs seeded on Matrigel
shown as a number of cord junctions per microscopic field. E: Formation of capillaries by endothelial cells from aortic rings isolated from WT or
db/db mice and plated on Matrigel. F: Formation of cords by HUVECs seeded on Matrigel and stimulated with empty medium (NC, negative
control) or conditioned media from WT PACs and db/db PACs, shown as a number of cord junctions per microscopic field. Each bar represents
mean + SEM. N = 4-5 (1A-E), N = 8-9 (1F), *p < 0.05, **p < 0.01 versus WT, ###p < 0.001 versus NC.
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checked whether impaired angiogenic potential of PACs
isolated from db/db mice can be corrected by rosiglita-
zone. Cells were exposed to rosiglitazone (10 μmol/L)
for 24 h. This resulted in a significant upregulation of
PPAR activity, which we tested using PPRE-luciferase
reporter plasmid (data not shown). To confirm PPARγ-
specificity, some cells were preincubated with GW9662
(10 μmol/L, 30 minutes), PPARγ antagonist.
Modulation of PPARγ activity did not influence signifi-
cantly the proliferation of PACs (Figure 2A), although
there was a tendency toward inhibition of proliferation in
cells treated with GW9662 (p = 0.08 and p = 0.07 in WT
and db/db cells). In contrast, migration (Figure 2B) and
formation of cord-like structures on Matrigel (Figure 2C),
two activities which were impaired in PACs isolated from
db/db mice, were rescued in db/db cells incubated with
rosiglitazone. This effect was at least partially blocked by
GW9662, confirming the PPARγ-dependency. Interest-
ingly, rosiglitazone did not improve migration or forma-
tion of cord-like structures in wild type PACs (Figure 2B,
C). Also, rosiglitazone showed a tendency to augment
angiogenic activity of mature endothelial cells (p = 0.08) in
aortal rings derived from db/db mice, without effects on
the cells isolated from wild type animals (Figure 2D,E).
Next, we tested effects of rosiglitazone (10 μmol/L, 24 h)
on expression of genes involved in angiogenesis, focusing
on two major agents, VEGF and SDF-1. Expression of
VEGF, similar in the cultured wild type and db/db PACs,
was upregulated in response to rosiglitazone. This upregu-
lation was slightly, but significantly weaker in cells isolated
from diabetic mice (Figure 3A). However, we did not see
changes on a protein level (data not shown). Expression ofKDR (Flk-1, VEGFR-2), the major receptor mediating the
proangiogenic VEGF action, was higher in db/db cells, and
not modified by rosiglitazone (Figure 3B), while Flt-1
(VEGFR-1) level was affected neither by diabetes nor by
rosiglitazone (Figure 3C). Like in the case of VEGF, expres-
sion of SDF-1 was similar in control wild type and db/db
PACs. Treatment with rosiglitazone showed a tendency
toward decrease in SDF-1 levels (Figure 3D), but this
effect did not reach statistical significance (p = 0.06 in
control PACs and p = 0.12 in db/db PACs). The same
trend was observed for protein level (data not shown).
Its major receptor, CXCR4 was, however, downregulated
in db/db cells, the effect not modified by rosiglitazone
(Figure 3E). Expression of CXCR-7 receptor was the
same in all experimental groups (Figure 3F). Additionally,
we found that both in wild type and db/db PACs rosigli-
tazone significantly increased production of KC, a potent
proangiogenic chemokine (Figure 3G). Cells cultured
with rosiglitazone showed also increased expression of
two genes which may promote differentiation of proan-
giogenic precursors, namely angiotensinogen (Figure 3H)
and proteolycan-4 (Figure 3I).
Effect of therapy with rosiglitazone on PACs and
endothelial cells in diabetic mice
Subsequently, we tested whether therapy with rosiglita-
zone would correct angiogenic functions of PACs and
mature endothelial cells in diabetic mice. As expected,
daily oral administration of rosiglitazone (10 mg/kg for
14 days) caused the increase in body mass by about 20%
of initial values (Additional file 3: Figure S2A). Concomi-
tantly, all measured biochemical parameters, like glucose,
cholesterol, and triglycerides concentrations, together with
Figure 2 Effect of PPARγ agonist rosiglitazone (ROSI, 10 μmol/L, 24 h) and PPARγ antagonist GW9662 (GW, 10 μmol/L, 24 h) on
angiogenic potential of PACs and endothelial cells from wild type (WT) or diabetic (db/db) mice. A: Proliferation of PACs.
Immunohistochemical detection of PCNA-positive cells. B: Migration of PACs in modified Boyden chambers. C: Formation of cords by PACs
seeded on Matrigel, shown as a number of cord junctions per microscopic field. D: Formation of capillaries by endothelial cells from aortic rings
isolated from WT or db/db mice and embedded in Matrigel. E: representative pictures showing aortic rings. Each bar represents mean + SEM,
expressed as percentage of values for untreated control. N = 4-5, #p < 0.05 versus control.
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cantly elevated in diabetic animals and reduced after treat-
ment with rosiglitazone (Additional file 3: Figure S2B-E).
Hematological parameters of peripheral blood were not
changed, apart from a total number of leukocytes, which
was lower in db/db mice, regardless of rosiglitazone treat-
ment (Additional file 1: Table S2).
Flow cytometric analysis showed that endothelial pro-
genitors (EPCs), defined as CD45−KDR+Sca-1+ cells, were
significantly less frequent in the bone marrow of diabetic
mice. Treatment with rosiglitazone resulted in a partial
restoration of bone marrow EPCs pool (Figure 4A, p =
0.06), which was complete after prolongation of treatment
time to 28 days (data not shown). Decreased frequency of
CD45−KDR+Sca-1+ cells was found also in the peripheral
blood of diabetic animals, although this tendency did not
reach statistical significance (Figure 4B). The number of
circulating EPCs was, however, strongly reduced in db/db
mice and not affected by rosiglitazone (Figure 4A-C).
In parallel with changes in the bone marrow EPC pool,
we observed a similar pattern (decrease in diabetic micepartially restored by rosiglitazone) in expression of
VEGF, both at the mRNA and protein levels (Figure 4D,
E). In contrast, concentration of VEGF in the blood was
the same in all experimental groups (Figure 4F). On the
other hand, expression of SDF-1 mRNA was the same
in the bone marrow of wild type and db/db mice,
but decreased in response to rosiglitazone (Figure 4G).
Concentration of SDF-1 protein did not reflect, however,
the level of mRNA expression and was increased in
rosiglitazone treated mice (Figure 4H). This increase was
not observed in the blood, where SDF-1 concentrations
were lower in diabetic animals (Figure 4I). Noteworthy,
expression of PPARγ in the bone marrow of diabetic db/
db mice was reduced by approximately 50% and was not
changed in response to rosiglitazone (Figure 4J).
We compared also the angiogenic potential of cultured
PACs isolated from diabetic animals treated for two weeks
with rosiglitazone with that from the untreated diabetic
mice or wild type animals. Analysis of PAC migration and
sprouting of capillaries from PAC spheroids showed the
impaired activity of cells derived from diabetic animals,
Figure 3 Effect of PPARγ agonist rosiglitazone (ROSI, 10 μmol/L, 24 h) on expression of proangiogenic genes in PACs from wild type
(WT) and diabetic (db/db) mice. PACs cultured without ROSI are used as a control. A: VEGF. B: KDR. C: Flt-1. D: SDF-1. E: CXCR4. F: CXCR7.
G: KC. H: Angiotensinogen. I: PRG-4. Quantitative RT-PCR. EF2 serves as an internal control. Each bar represents mean + SEM. N = 8-10, *p < 0.05,
**p < 0.01 versus WT, #p < 0.05, ##p < 0.01, ###p < 0.001 versus control.
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the correction of metabolic status (data not shown). Simi-
larly, paracrine potential of PACs and angiogenic activity
of mature endothelial cells isolated from aorta were not
rescued in diabetic mice treated with rosiglitazone (data
not shown).
Conditioned media from PACs improve blood flow
restoration in diabetic mice
We checked whether PACs isolated from nondiabetic,
wild type individuals may improve the blood flow restor-
ation in ischemic muscles after hind limb ischemia in dia-
betic mice. To assess the importance of paracrine activity
of PACs we compared effect of a) locally transplanted
PACs and b) locally injected conditioned media harvested
from PACs. Femoral artery ligation in db/db mice was
followed either by injection of non-conditioned, empty
medium ("control"), PACs isolated from syngeneic wild
type mice and cultured in vitro ("cells"), or conditioned
media harvested from such cells ("media"). Measurements
of perfusion done immediately after surgery (day 0) and
on days 7th, 14th, 21st, and 28th showed that blood flow
recovery in control diabetic mice was not effective, as on
day 28th it still did not reach a 50% of perfusion measured
before surgery. However, this process was enhanced inanimals injected with conditioned media on day 28th, what
confirms the importance of paracrine influence of bone
marrow derived cells. Transplantation of PACs was less
effective, or could even slow down the recovery from
ischemia at early time points (Figure 5A). There was also
a tendency toward a higher proportion of regenerating
fibers in the group injected with conditioned media in
comparison to control group (Figure 5B), not significant
in the group subjected to PAC transplantation (p > 0.3).
Immunohistochemical analyzes performed on day 28th
showed no differences in density of CD31-positive capil-
laries between experimental groups (Figure 5C). However,
there was a higher number of αSMA-positive arterioles in
animals treated with conditioned media and a similar ten-
dency in the group after PAC transplantation (Figure 5D).
No statistically significant changes in frequency or number
of CD45−KDR+Sca-1+ cells were found at this time point
either in bone marrow or in peripheral blood (data not
shown).
Gene expression profiles of PACs
To better understand the effect of diabetes on proangio-
genic potential of the bone marrow-derived cells we
compared a transcriptome of PACs isolated from the
wild type and db/db mice. Additionally, for cells of both
Figure 4 Effect of oral daily administration of PPARγ agonist rosiglitazone (ROSI, 10 mg/kg of body weight, 14 days) on endothelial
progenitor cells and expression of proangiogenic genes in diabetic (db/db) mice. Control db/db and wild type (WT) mice were treated
with vehicle. A: Percentage of CD45−KDR+Sca-1+ cells in bone marrow. B: Percentage of CD45−KDR+Sca-1+ cells in peripheral blood. C: Number
of CD45−KDR+Sca-1+ cells in peripheral blood. Multicolor FACS phenotyping. D: Expression of VEGF mRNA in bone marrow. Quantitative RT-PCR.
EF2 serves as an internal control. E: Concentration of VEGF protein in bone marrow. F: Concentration of VEGF protein in peripheral blood. ELISA.
G: Expression of SDF-1 mRNA in bone marrow. Quantitative RT-PCR. EF2 serves as an internal control. H: Concentration of SDF-1 protein in bone
marrow. I: Concentration of SDF-1 protein in peripheral blood. ELISA. J: Expression of PPARγ mRNA in bone marrow. Quantitative RT-PCR. EF2
serves as an internal control. Each bar represents mean + SEM. N = 8-10 (4A-C, F, I), N = 4-6 (4D, E, G, H, J), *p < 0.05, **p < 0.01, ***p < 0.001 versus
WT, #p < 0.05 versus db/db.
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hypoxia, the most important proangiogenic stimulus.
Results are summarized in Table 1. Generally, the influ-
ence of hypoxia (2% O2 for the final 24 h incubation
period) on gene expression was similar in the wild type
and db/db cells, mainly leading to upregulation of genes
involved in energetic metabolism, especially in glycolysis.
Comparison of wild type and db/db PACs cultured in
normoxia revealed that ~700 transcripts were differen-
tially expressed (p < 0.05), including 54 transcripts with
more than two-fold difference (p < 0.01). Analysis of
molecular pathways using GeneGO platform indicated
that db/db PACs displayed higher expression levels of
pro-oxidative genes, such as NADPH-4 oxidase (Nox4),p22phox subunit, or protein kinase C-δ (PKCδ). It was ac-
companied by lower levels of cytoprotective genes, such
as glutathione S-transferases (GST-1 and GST-3) or gluta-
thione peroxidase-4 (GPX-4) (Table 1). PACs isolated
from diabetic mice had also increased expression of proin-
flammatory genes, e.g. tumor necrosis factor receptor-1
(TNFR-1), granulocyte-colony stimulating factor-3 recep-
tor (G-CSF-3R), CXCL16 chemokine, or P-selectin ligand
(Table 1). Similarly, genes associated with remodeling of
extracellular matrix, such as MMP-2, MMP-9, MMP-14
and MMP-23 matrix metalloproteinases were upregulated
in db/db cells (Table 1). Diabetic PACs had also higher
expression of integrin-α1, −β2 and -β4 mRNAs, with
concomitant lower expression of genes responsible for
Figure 5 Restoration of blood flow in ischemic muscles in diabetic (db/db) mice subjected to the hind limb ischemia. Ischemic
gastrocnemius was injected either with empty media (control, EBM-2 with 0.5% FBS), conditioned media (media, EBM-2 with 0.5% FBS harvested
from cultured wild type PACs ), or PACs (cells, 2.5 x 105 in control medium) 24 h after surgery (injections into 3 sites, total volume of 50 μL).
A: Blood flow expressed as a ratio between ischemic and control leg. Numerical data and representative pictures. Laser-Doppler flowmetry.
B: Percentage of regenerating fibers in gastrocnemius muscle, 28 days after surgery. Hematoxylin-eosin staining. C: Number of capillaries in
gastrocnemius muscle, 28 days after surgery. Immunohistochemical staining for CD31. D: Number of arterioles in gastrocnemius muscle, 28 days
after surgery. Immunohistochemical staining for αSMA. Numerical data and representative pictures. N = 4-6, *p < 0.05, **p < 0.01 versus control.
Kotlinowski et al. Cardiovascular Diabetology 2014, 13:150 Page 9 of 19
http://www.cardiab.com/content/13/1/150filopodia formation, like efexin (NGEF) or T-complex
protein-1 subunit-β (CCT2) (Table 1), what might
be associated with the impaired migration capacity of
db/db cells. Importantly, expressions of proangiogenic
genes, such as fibroblast growth factor-7 (FGF-7),
VEGF-C, VEGF-D, or angiogenin, were decreased in
PACs isolated from diabetic animals (Table 1).
Expression of PPARγ in PACs
Transcriptome analysis showed that PACs isolated from
db/db mice had reduced expression of PPARγ (Figure 6A).
This decrease seems to have a functional effect, as sug-
gested by changes in expression of PPARγ targeted genes
(Figure 6). We found 8 genes known to be directly regu-
lated by PPARγ [37], which were differently expressed
in PACs from wild type and db/db mice. Interestingly,
expressions of genes positively regulated by PPARγ [38-42],
namely forkhead box-A1 (FoxA) (Figure 6B), caveolin-
1 (Figure 6C), 11β-hydroxysteroid dehydrogenase type
1 (HSD11β1) (Figure 6D), stearoyl-CoA desaturase-1
(SCD-1) (Figure 6E), and perilipin (Figure 6F) weredecreased in db/db PACs. In contrast, expression of
genes negatively regulated by PPARγ [43,44], namely
collagen-1α2 (Figure 6G), pregnancy associated plasma
protein-A (PAPP-A) (Figure 6H), and Nox4 (Figure 6I)
were increased in db/db PACs.
PPARγ heterozygosity in normoglycemic mice does not
impair PAC functions
Proper level of PPARγ is necessary for development of pla-
centa vasculature [30,45], pointing to role of PPARγ in
angiogenesis. In diabetic db/db mice impaired angiogenesis
and decrease in number of PACs in bone marrow or
peripheral blood is accompanied by the reduced expression
of PPARγ both in PACs (Figure 6A) and in bone marrow
(Figure 4J). Therefore one can hypothesize that downregu-
lation of PPARγ expression may be a primary cause of the
impairment in PAC or endothelial cell angiogenic potential.
To verify this supposition, in the last set of experiments
we investigated angiogenesis in normoglycemic mice car-
rying one dysfunctional allele of PPARγ (PPARγ+/−). Such
animals had a decreased PPARγ mRNA expression both
Table 1 Analysis of transcriptome of PACs isolated from bone marrow of wild type (WT) or diabetic (db/db) mice and
cultured in vitro for 9 days
Gene Normoxia Hypoxia
Oxidative stress and cytoprotection WT db/db WT db/db
Nox4 (NOX4) 148 ± 20.3 245 ± 15.2* 153 ± 25.0 302 ± 123.8# 0.082
Cyba (p22phox) 29331 ± 1383.1 35829 ± 1277.4** 28248 ± 2195.8 34380 ± 5610.4
Prkcd (PKCδ) 3134 ± 75.8 3698 ± 286.6* 3667 ± 518.5 3965 ± 413.3
Chst1 (GST-1) 6979 ± 411.2 4412 ± 341.3** 8339 ± 562.9 5774 ± 374.8*#
Mgst3 (GST III) 3388 ± 453.1 1741 ± 100.7* 4076 ± 590.9 2563 ± 342.6* 0.070; #0.091
Gpx4 (GPX4) 7819 ± 354 6920 ± 423.3* 8394 ± 76.9# 7599 ± 614.9* 0.076; #0.099
Inflammation WT db/db WT db/db
Tnfrsf1a (TNFR-1) 1259 ± 68.7 1447 ± 124.7* 0.051 1103 ± 298.5 1147 ± 82.5#
Csf3r (G-CSF3R) 188 ± 6.7 214.9 ± 9.5* 209 ± 7.9 237 ± 36.1
Cxcl16 (CXCL16) 2328 ± 215.3 3194 ± 403.5* 2464 ± 319.2 2972 ± 535.2
Selplg (P-selectin ligand) 1930 ± 219.1 2758 ± 324.4* 2737 ± 822.8 3214 ± 311.0# 0.077
Extracellular matrix remodeling WT db/db WT db/db
Mmp2 (MMP-2) 2825 ± 395.2 6498 ± 1373.3* 2567 ± 900.6 6454 ± 905.8**
Mmp9 (MMP-9) 1906 ± 1005.0 7554 ± 4171.7* 0.069 1713 ± 637.0 9625 ± 955.3***
Mmp14 (MMP-14) 5081 ± 513.8 5965 ± 461.9* 5499 ± 518.5 5758 ± 519.5
Mmp23 (MMP-23) 1625 ± 273.8 2127 ± 267.9* 2396 ± 521.2# 0.054 2956 ± 338.2#
Migration and proliferation WT db/db WT db/db
Itgam (integrin-α1) 983 ± 254.4 1397 ± 30.8* 0.052 1499 ± 313.8# 0.096 1397 ± 498.6*
Itgb2 (integrin-β2) 354 ± 37.4 438 ± 30.9* 472 ± 76.2# 587 ± 90.8* 0.085#
Itgb4 (integrin-β4) 105 ± 11.2 141 ± 4.28* 178 ± 66.0# 0.096 187 ± 26.7#
Ngef (NGEF) 163 ± 2.9 104 ± 8.2** 246 ± 36.2# 140 ± 5.7*##
Cct2 (CCT2) 166 ± 4.0 139 ± 4.9** 136 ± 11.6# 145 ± 16.6
Msx1 (MSX-1) 184 ± 18.5 132 ± 13.7** 159 ± 17.8# 0.081 127 ± 1.24*
Cdkl2 (CDKL2) 233 ± 17.3 177 ± 7.4** 205 ± 19.7# 0.066 193 ± 15.9
Areg (AREG) 322 ± 69.7 118 ± 14.5* 290 ± 126.6 155 ± 39.4* 0.099
Mdk (midkin) 236 ± 6.9 313 ± 21.6** 184 ± 3.1### 300 ± 17.9**
Nos3 (NOS3) 122 ± 3.0 142 ± 5.2** 99 ± 7.4# 106 ± 6.3###
Cav1 (caveolin-1) 4279 ± 675.2 2171 ± 242.9* 6460 ± 418.0## 4889 ± 968.4*#
Fgf7 (FGF-7) 7073 ± 780.0 5858 ± 795.5* 0.066 5736 ± 403.8# 5306 ± 958.3
Ang2 (angiogenin) 198 ± 50.5 138 ± 15.9* 0.085 164 ± 42.4 131 ± 6.1
Vegfb (VEGF-B) 1637 ± 107.1 1641 ± 91.4 2396 ± 97.9### 2195 ± 246.8#
Vegfc (VEGF-C) 714 ± 69.2 524 ± 91.5* 730 + 111.0 904 ± 331.3# 0.089
Vegfd (VEGF-D) 791 ± 50.7 499 ± 105.6* 1011 ± 289.9 839 ± 113.8##
For last 24 h cell were incubated in normoxia (21% O2) or hypoxia (2% O2).
Means ± SEM of normalized fluorescence signal. N = 3 for each gene, *p < 0.05, **p < 0.01 WT versus db/db, #p < 0.05, ##p < 0.01, ###p < 0.001 normoxia versus
hypoxia. For 0.05 < p < 0.1 exact p values are shown.
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to a similar extent as in db/db mice. They also had a
more proinflammatory phenotype, as illustrated by
higher concentrations of sVCAM-1, soluble intercellular
adhesion mulecule-1 (sICAM-1), IL-6, and IL-1β in the
blood (Figure 7C-F). No differences were found, however,
between expressions of genes regulating angiogenic activ-
ity (VEGF, KDR, SDF-1, and CXCR4) in PACs isolatedform PPARγ+/+ and PPARγ+/− animals (Additional file 4:
Figure S3A-D). Also frequency of CD45−KDR+Sca-1+
endothelial precursors were similar in both groups
(Additional file 4: Figure S3E-F). Based on transcrip-
tome analysis of PACs isolated from WT and db/db
mice we selected a candidate genes to verify effects of
PPARγ haplodeficiency and hypoxia on their expression.
Cells isolated from PPARγ+/− animals did not display
Figure 6 Expression of PPARγ associated genes in PACs from diabetic (db/db) mice, shown as a percentage of gene expression in
PACs from wild type (WT) mice. A: PPARγ. B: FoxA1. C: caveolin-1. D: HSD11β. E: SCD-1. F: perilipin. G: collagen-1α. H: PAPP-A. I: Nox4.
Quantitative RT-PCR. EF2 serves as an internal control. Each bar represents mean + SEM. N = 3, *p < 0.05, **p < 0.01 versus WT.
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p22phox), nor lower levels of cytoprotective genes (GST-
3, Table 2). Despite lower expression of PPARγ in such
cells, than in WT ones they were characterized by the
same mRNA amount of proinflammatory genes (TNFR-1,
P-selectin ligand) and matrix metalloproteinases MMP-2,
MMP-9 (Table 2). Similarly, genes associated with proan-
giogenic properties of PACs (VEGF, SDF-1 and their
receptors) were expressed at the same level in PPARγ+/+
and PPARγ+/− cells. However, CAV1 was upregulated in
PPARγ+/− PAC (Table 2).
In earlier experiments we have demonstrated that angio-
genesis induced in response to skin injury is impaired in
the db/db diabetic mice, what is accompanied by defective
wound healing [31]. Here we performed similar experi-
ment using PPARγ+/+ and PPARγ+/− animals subjected to
full thickness skin excision. Reduced expression of PPARγ
influenced neither skin wound closure rate (Figure 8A)
nor injury-induced increase in number of capillaries
within the wounded tissue (Figure 8B,C).
Then, we compared the efficacy of angiogenesis
employing the model of blood flow restoration in
PPARγ+/+ and PPARγ+/− animals subjected to hind limb is-
chemia (Additional file 5: Figure S4A-H). Femoral artery
ligation did not affect expression of VEGF in bone marrow
or ischemic muscle (Additional file 5: Figure S4A,B), as
demonstrated by qRT-PCR analysis performed on day 1
after surgery. In the same time, the expression of SDF-1 did
not change significantly in the bone marrow (Additional
file 5: Figure S4C), but was upregulated in the muscle(Additional file 5: Figure S4D). The muscular levels of
KDR were similar before and one day after artery
ligation (Additional file 5: Figure S4E), whereas expres-
sion of CXCR4 showed a tendency toward upregulation
(Additional file 5: Figure S4F, p = 0.08 and p = 0.09 for
PPARγ+/+ and PPARγ+/− mice, respectively).
We found some differences between genotypes in re-
sponse to hind limb ischemia. First, untreated PPARγ+/− in-
dividuals had a higher number of circulating granulocytes,
whereas numbers of monocytes and lymphocytes were
similar in both experimental groups. One day after femoral
artery ligation numbers of monocytes and granulocytes in
the peripheral blood decreased significantly in PPARγ+/−
mice, but remained stable in their wild type counterparts
(Figure 9A). This was accompanied by significantly higher
leukocytic infiltration of ischemic muscle in the PPARγ+/−
individuals, observed on day 1st and 14th after artery
ligation (Figure 9B). Second, we found more regenerating
muscle fibers, with centrally located nuclei, on day 14th
after induction of ischemia in mice with lower expression
of PPARγ (Figure 8C). Nevertheless the restoration of blood
flow in ischemic muscle monitored on day 1st, 7th, and 14th,
as well as number of capillaries counted on day 14th were
the same, regardless of PPARγ genotype (Figure 9D,E).
Discussion
Angiogenic potential of PACs and mature endothelial
cells is impaired in db/db mice. We demonstrated that it
can be restored by activation of PPARγ in cells cultured
with rosiglitazone. We also found that diabetes is associated
Figure 7 Proinflammatory phenotype of PPARγ haplodeficient mice. A-B: Expression of PPARγ in wild type (WT) and PPARγ heterozygotic
(PPARγ+/−) mice. A: bone marrow. B: PACs. Quantitative RT-PCR. EF2 serves as an internal control. C-F: Concentration of inflammatory mediators in
the blood plasma of WT and PPARγ-HT mice. C: sVCAM-1. D: sICAM-1. E: IL-6. F: IL-1β. Milliplex®MAP platform. Each bar represents mean + SEM.
N = 4-6, *p < 0.05, **p < 0.01 versus WT.
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hypothesize that decreased level of PPARγ may contribute
to the inhibition of neovascularization observed in diabetic
individuals. Experiments performed in normoglycemic
PPARγ haplodeficient mice showed, however, that this is
not the case and reduced expression of PPARγ does not
affect angiogenesis.
Dysfunction and disturbed angiogenic potential of endo-
thelial cells in diabetes have been comprehensively studied
[4]. Much less is known about effect of diabetes on vascu-
logenic activities of the bone marrow-derived cells. We
compared angiogenic potential of PACs, the mononuclear
cells isolated from bone marrow of wild type or db/db mice
and cultured under conditions promoting endothelial dif-
ferentiation. Our analysis showed that cells derived from
db/db mice displayed reduced angiogenic capacities. Espe-
cially, they demonstrated impaired migration, formation of
cord-like structures on Matrigel and capillary outgrowth
from spheroids. Only the proliferation rate was not signifi-
cantly affected. Our results are in accordance with other
studies showing decreased angiogenic potential of diabetic
EPC isolated both from humans and animals [13-17].Recently published paper by Li et al., demonstrated that
advanced glycation end products (AGE) that are present in
diabetes induce EPC apoptosis, impair SDF-1 and NO
production [46]. Deleterious effects of diabetes was also
reported for mesenchymal stem cells in humans [47].
Transcriptome analysis suggests a reduced capacity of
db/db PACs to counteract ROS production. The results
may also suggest that their impaired migration can be
associated with upregulation of integrins accompanied
by downregulation of genes involved in filopodia forma-
tion, such as efexin or CCT2 [48]. Furthermore, PACs
isolated from db/db mice showed decreased paracrine
potential, what might be related to decreased expression
of VEGF-C, VEGF-D, FGF7 or angiogenin.
It has been demonstrated that PPARγ ligands influence
angiogenesis, acting generally as proangiogenic agents,
and increasing number of bone marrow derived endo-
thelial progenitors. In animal models, such as diabetic
rats, treatment with pioglitazone increased density of ca-
pillaries in the heart and skeletal muscle by a mechanism
unrelated to VEGF-mediated angiogenesis [5]. Proangio-
genic effect of pioglitazone, associated with accelerated
Table 2 Analysis of gene expression in PACs isolated from bone marrow of wild type (PPARγ+/+) or PPARγ
haplodeficient mice (PPARγ+/−) and cultured in vitro for 9 days
Gene Normoxia Hypoxia
Oxidative stress and cytoprotection PPARγ+/+ PPARγ+/− PPARγ+/+ PPARγ+/−
Nox4 (NOX4) 0,00065 ± 0,00012 0,00090 ± 0,00016 0,00052 ± 0,00008 0,00129 ± 0,00023*
Cyba (p22phox) 0,702 ± 0,102 0,748 ± 0,094 0,449 ± 0,077 0,829 ± 0,185
Mgst3 (GST III) 0,043 ± 0,005 0,060 ± 0,006* 0,043 ± 0,004 0,060 ± 0,005*
Inflammation PPARγ+/+ PPARγ+/− PPARγ+/+ PPARγ+/−
Tnfrsf1a (TNFR-1) 0,178 ± 0,028 0,235 ± 0,017* 0.092 0,132 ± 0,015 0,173 ± 0,012* 0.051##
Selplg (P-selectin ligand) 0,00018 ± 0,00008 0,00021 ± 0,00005 0,00019 ± 0,00004 0,00031 ± 0,00006
Extracellular matrix remodeling PPARγ+/+ PPARγ+/− PPARγ+/+ PPARγ+/−
Mmp2 (MMP-2) 0,070 ± 0,005 0,086 ± 0,010 0,044 ± 0,003## 0,101 ± 0,029* 0.081
Mmp9 (MMP-9) 0,416 ± 0,124 0,194 ± 0,067 0,263 ± 0,067 0,148 ± 0,033
Migration and proliferation PPARγ+/+ PPARγ+/− PPARγ+/+ PPARγ+/−
Nos3 (NOS3) 0,00049 ± 0,00006 0,00063 ± 0,00013 0,00044 ± 0,00005 0,00061 ± 0,00009
Cav1 (caveolin-1) 0,051 ± 0,006 0,080 ± 0,007** 0,104 ± 0,010## 0,162 ± 0,008**,###
Sdf-1 (CXCL12) 0,069 ± 0,021 0,110 ± 0,022 0,071 ± 0,022 0,088 ± 0,010
Cxcr4 (CXCR-4) 0,023 ± 0,007 0,023 ± 0,004 0,033 ± 0,006 0,037 ± 0,004#
Cxcr7 (CXCR-7) 0,0021 ± 0,0005 0,0021 ± 0,0003 0,0095 ± 0,0020# 0,0081 ± 0,0013##
Vegfa (VEGF-A) 0,052 ± 0,005 0,051 ± 0,005 0,185 ± 0,047# 0,164 ± 0,008###
Flt-1 (VEGFR-1) 0,00028 ± 0,00004 0,00038 ± 0,00011 0,00045 ± 0,00003# 0,00065 ± 0,00019
KDR (VEGFR-2) 0,0021 ± 0,0002 0,0027 ± 0,0007 0,0013 ± 0,0005 0,0019 ± 0,0003
For last 24 h cell were incubated in normoxia (21% O2) or hypoxia (2% O2). Quantitative RT-PCR, EF2 serves as an internal control. Means ± SEM. N = 5-6, *p < 0.05,
**p < 0.01 PPARγ+/+ versus PPARγ+/−, #p < 0.05, ##p < 0.01, ###p < 0.001 normoxia versus hypoxia. For 0.05 < p < 0.1 exact p values are shown.
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rats [49]. What is more, pioglitazone prevented EPC
from apoptosis via PI3K/Akt signaling pathway [50].
Yet another study proved that beneficial effects of
PPARγ activation might be also obtained by using other
compounds. A dual PPARα/γ agonist, aleglitazar, ad-
ministrated to mice at a 10 mg/kg/day dose increased the
number and function of circulating angiogenic cells.
Furthermore, aleglitazar reduced oxidative stress-induced
apoptosis and p53 expression, while phosporylation of
eNOS and Akt was elevated [51]. On the other hand, a
deleterious effect on EPC biology was demonstrated for
too strong PPARγ activation by palmitic acid. Palmitic acid
is a natural PPARγ ligand which concentration increases
in diabetes leading to impairment of EPC migration and
proliferation by PPARγ-mediated STAT5 transcription in-
hibition [52]. Importantly, improved function of EPC and
endothelial cells were described in diabetic patients under
rosiglitazone therapy [19,20], the effect resulting possibly
from reduced generation of ROS and improved bioavail-
ability of NO [19]. In individuals with diabetes it is not
easy, however, to discriminate the effects of metabolic cor-
rection and direct regulation of angiogenic capacities of
endothelial or bone marrow-derived cells.
In our studies, to activate PPARγ in vitro in PACs
we used rosiglitazone at the dose of 10 μmol/L. Asdemonstrated by Cox et al., a single oral dose of rosiglita-
zone (8 mg) in humans leads to a maximal concentration
of 603 ng/mL (1.69 μmol/L) in the plasma [53]. Rosiglita-
zone is one of three thiazolidinediones introduced in the
treatment of type 2 diabetes. Rosiglitazone provided a sus-
tained glycemic control and seemed able to slow down the
progression towards T2DM in patients with impaired glu-
cose tolerance [54]. We demonstrated a direct effect of
PPARγ activation on PACs angiogenic potential. Incubation
of db/db PACs with rosiglitazone in vitro, improved their
migration, formation of cord-like structures and capillary
outgrowth. These effects were probably PPARγ-dependent,
as were prevented by preincubation of cells with GW9662,
PPARγ antagonist. Similar increase in migratory capacities
of cultured bone marrow derived cells was observed earlier
after treatment with pioglitazone or troglitazone [21,22,26]
which may be mediated by reduced expression of ICAM-1
and VCAM-1 adhesion molecules [55]. Beneficial effects of
PPARγ activation by rosiglitazone was also proved for vas-
cular smooth muscle cells. Rosiglitazone treatment resulted
in increased protein kinase G activity leading to attenuated
hyperplasia after vascular injury [56].
There are, however, studies showing the antiangiogenic
activity of PPARγ. In fact, in the first report, Murata
et al. described a significant decrease in migration and
proliferation of choroidal endothelial cells exposed to
Figure 8 Healing of cutaneous wounds in wild type (WT) and
PPARγ haplodeficient (PPARγ+/−) mice. A: Closure of wounds
expressed as percentage of non-epithelialized area. Surface of
wound measured immediately after surgery was taken as 100%.
B: Number of capillaries stained for CD31 antigen in the muscles
located under healthy skin (day 0) and under wounded skin, 3 and
11 days after surgery. C: Representative pictures showing CD31
immunostaining. Fluorescence microscopy. Mean + SEM. N = 4-5,
***p < 0.001 versus day 0.
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zone suppressed HUVEC migration, the effect not re-
versed by GW9662, so possibly independent of PPARγ
[27]. Also KR-62980, another PPARγ agonist reduced
HUVEC migration and formation of cord-like struc-
tures on Matrigel, which was accompanied by apoptotic
cell death [28]. The reason of such discrepancies are
not clear. One can suppose that concentration of
PPARγ ligands used in some experiments was high and
therefore proapoptotic [27,28,57]. Another possibility isthat ligands of PPARγ might have different effect on
endothelial cells from different vascular beds. The well
characterized PPARγ target gene is CD36, receptor for
antiangiogenic thrombospondin-1 (TSP1), and its up-
regulation by PPARγ agonist may inhibit endothelial
functions [58]. CD36 is expressed mainly on micro-
vascular endothelial cells, and at lower level on venous
endothelium [59]. Moreover, even in microvasculature
the expression of CD36 is organ specific, with the
highest level in the heart, muscle and lungs and very
low in the bone marrow [60]. One could suppose that
such differences may modify the angiogenic response
to PPARγ agonists.
We also showed that in vivo administration of rosigli-
tazone partially restored EPC population in the bone
marrow, although not in the peripheral blood. Analysis
of gene expression revealed that db/db mice have a de-
creased level of VEGF and unchanged SDF-1 in the bone
marrow. In such animals, rosiglitazone showed only a
tendency toward upregulation of VEGF, but significantly
affected SDF-1. Concentration of SDF-1 protein in the
bone marrow increased, while remained unchanged in
peripheral blood, thus the gradient of SDF-1 possibly was
enhanced. The results were, however, complex: increase
in concentration of SDF-1 protein in the bone marrow
was not reflected by expression of SDF-1 mRNA, which
was even lower after rosiglitazone administration. This
suggests that rosiglitazone may influence SDF-1 not pri-
marily at the mRNA level. Similar discrepancy between
SDF-1 mRNA and protein expression was observed, for
instance, in murine bone marrow after stimulation with
granulocyte colony stimulating factor (G-CSF) [61]. Here,
the possible mechanism was ascribed to regulation of
proteases which are known to degrade SDF-1, such as
MMP-9, MMP-2, neutrophil elastase or cathepsin G [60].
Indeed, MMP-9 and MMP-2 are inhibited by PPARγ ago-
nists [27]. Similarly to our finding a decreased expression
of SDF-1 was detected in magnetically sorted EPC cells
isolated from bone marrow of diabetic mice [62].
Bone marrow derived cells may facilitate angiogenesis,
mainly through paracrine effects. Our in vitro experi-
ments revealed that paracrine activity of PACs isolated
from db/db mice is impaired. Therefore we checked
whether the wild type cells may be useful in therapeutic
neovascularization and restoration of proper blood
perfusion in ischemic muscles of diabetic animals. To
this aim we induced hind limb ischemia in db/db mice,
and then treated them with PACs collected from syngen-
eic, healthy animals or with conditioned media harvested
from such cells. It turned out that a single intramuscular
injection of conditioned media facilitates restoration of
perfusion. Importantly, delivery of PACs themselves was
ineffective, or even detrimental at early time points,
what might suggest that a massive death of injected cells
Figure 9 (See legend on next page.)
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Figure 9 Effect of induction of hind limb ischemia in wild type (WT) and PPARγ haplodeficient (PPARγ+/−) mice. A: Number of
lymphocytes (Ly), granulocytes (Gr) and monocytes (Mo) in the peripheral blood of WT and PPARγ+/− mice before (d 0) and 1 day (d 1) after
surgery. Automated hematology analyzer. B: Leukocytic infiltration of gastrocnemius muscle before (d 0) and 14 and 28 days (d 14 and d 28) after
surgery. Semiquantitative analysis and representative pictures. Hematoxylin-eosin staining. C: Percentage of regenerating fibers in ischemic muscle,
28 days after surgery. Numerical data and representative picture. Hematoxylin-eosin staining. D: Blood flow expressed as a ratio between ischemic
and control leg. Numerical data and representative pictures. Laser-Doppler flowmetry. E: Number of capillaries in the ishcmic muscle, 28 days after
surgery. Immunohistochemical staining for CD31. Mean + SEM. N = 5-9 (9A-C, E), N = 10 (9D), *p < 0.05, **p < 0.01, ***p < 0.001 versus d 0; #p < 0.05,
##p < 0.01, ###p < 0.001 versus WT.
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sible explanation for lack of efficacy of PAC delivery can
be a low proportion of cells surviving at the site of trans-
plantation. Recently we showed that after intradermal
PAC injection approximately 70% of cells were removed
in first six hours, and less than 1% were present one week
later at the site of delivery [12]. This supposition on too
low number of surviving cells can be indirectly supported
by results described by Di Santo and colleagues, who
showed beneficial, proangiogenic effects of both condi-
tioned media and cells in a rat model of chronic hind
limb ischemia. They used, however, serial intramuscular
injections (instead of single injection) and higher number
of cells (1 × 106 instead of 2.5 × 105 cells) [63]. Our
results indicate that cell free conditioned media may
be an alternative for therapeutic angiogenesis in ische-
mic muscles. Beneficial effects of conditioned media
from PACs, adipose-derived or bone marrow-derived
mesenchymal stem cells have already been described
by our and other teams in ischemic muscles in mice
and rats [12,64,65].
Analysis of gene expression showed that PACs isolated
from db/db mice displayed higher VEGFR-2 and lower
CXCR4 receptor levels than their wild type counterparts.
Incubation of PACs with rosiglitazone did not affect
VEGFR-2 and CXCR4 expressions, but upregulated VEGF
and KC, both in wild type and db/db PACs. These results
are in accordance to earlier studies. Transcriptional upreg-
ulation of VEGF was first time reported in rat and human
vascular smooth muscle cells stimulated in vitro with
ciglitazone or rosiglitazone [24,25]. These observations
were then confirmed in vascular smooth muscle cells in
human atheromatous aortas [66,67]. Moreover, PPARγ
activation increased VEGF production in murine adi-
pose tissue [23,68] and cornea [69]. Also in patients
with type-2 diabetes the level of VEGF and IL-8 were
increased under pioglitazone therapy [70]. Importantly,
administration of PPARγ agonists improved revascular-
ization in muscle subjected to hind limb ischemia in
mice [71] and enhanced angiogenesis in ischemic brain
in rats [32]. Additionally, we noticed that rosiglitazone
increased expression of PRG4 and angiotensinogen in
cultured PACs. This observation seems interesting
as PRG4 can promote development of hemangioblasts[72] and similar role has been ascribed to the angioten-
sin converting enzyme [73].
Influence of diabetes on PPARγ expression is not ap-
parent. Direct comparison showed the same levels of
PPARγ in adipocytes and aorta of db/db (diabetic) and
db/m (non-diabetic) mice [74]. Analysis performed in
rats, where diabetes was induced with streptozotocin
(STZ), suggested the tissue specific effects – expression
of PPARγ was increased in aorta, but decreased in renal
cortex or retina [75]. However, decreased expression of
PPARγ can also be expected in diabetic and obese pa-
tients, as inverse correlation was found between the body
mass index (BMI) and PPARγ level in human adipocytes
[76]. Noteworthy, PPARγ is downregulated by AGE [77]
and TNFα [78], overproduced in obesity and type 2
diabetes. Recently, Biscetti et al. described the reduced ex-
pression and activity of PPARγ in muscles of STZ-treated
diabetic mice subjected to hind limb ischemia. This was
accompanied by decreased production of VEGF and im-
paired neovascularization [69]. In accordance, we found
significantly lower level of PPARγ mRNA either in bone
marrow or in cultured PACs derived from db/db mice.
This decrease had possibly a functional effect, as sug-
gested by changes in expression of PPARγ target genes.
One can than suppose that tight regulation of PPARγ
expression is necessary for proper angiogenesis. Hence,
PPARγ−/− mice displayed vasculature defects in placentas,
correlated with an unsettled balance of pro- and antian-
giogenic factors [30,45]. On the other hand, treatment of
pregnant wild-type mice with rosiglitazone also resulted in
a disorganization of the placental microvasculature [30].
Our results indicate, however, that ~50% decrease in
expression of PPARγ in normoglycemic PPARγ+/− mice
does not affect angiogenesis in wound healing or hind
limb ischemia models. What is more, PACs isolated from
PPARγ+/− mice do not resemble gene expression pattern
observed in diabetic cells. Thus, we assume that similar
decrease found in diabetic animals does not contribute to
impaired angiogenesis.
In summary, activation of PPARγ with rosiglitazone
improves angiogenic potential of PACs and endothelial
cells, impaired in diabetes. We showed that expression of
PPARγ is decreased in diabetic db/db mice, however
similar decrease in normoglycemic PPARγ+/− mice does
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angiogenic potential in db/db mice is independent of
decreased expression of PPARγ. We showed also that
paracrine activity of PACs is sufficient to improve
neovascularization in ischemic muscle of diabetic mice.
Therefore, application of conditioned media harvested
from PACs can be proposed as effective and safe alter-
native to proangiogenic cell transplantation.
Additional files
Additional file 1: Supplemental Methods and Results.
Additional file 2: Figure S1. Characterization of PACs isolated from
murine bone marrow and cultured in vitro for 10 days. A: Bright field
photograph of PACs. Representative picture, magnification ×100. B:
Uptake of DiI-AcLDL (red) by PACs. Representative picture, magnification
×100. C: Binding of BS1 lectin (green) by PACs. Representative picture,
magnification ×100. D: Formation of cords by PACs stained with
DiI-AcLDL (red) and seeded on matrigel. Representative picture,
magnification ×100. E: Fraction of cells expressing CD45, KDR, CXCR4 or
SCA-1 antigens in PAC populations isolated from wild type (WT) or
diabetic (db/db) mice after a 10-day incubation period. Flow cytometry
phenotyping. Each bar represents mean + SEM. N = 3, **p < 0.01, ***p < 0.001
versus WT.
Additional file 3: Figure S2. Body mass and blood biochemical
parameters in wild type (WT) and diabetic (db/db) mice fed daily for two
weeks either with vehicle (WT and db/db) or with rosiglitazone (db/db +
ROSI, 10 mg/kg of body weight) and analyzed 14 days after surgery.
A: Body mass before treatment (d 0) and at 14th day of treatment (d 14).
B: Concentration of glucose. C: Percentage of glycated hemoglobin.
D: Concentration of cholesterol. E: Concentration of triglycerides.
Automated biochemistry analyzer. Each bar represents mean + SEM.
N = 20, ***p < 0.001 versus WT, ##p < 0.01, ###p < 0.001 versus untreated
db/db, ^^^p < 0.001 versus d 0).
Additional file 4: Figure S3. Expression of angiogenic genes in
cultured PACs and presence of CD45−KDR+Sca-1+ cells in bone
marrow or peripheral blood of wild type (WT) and PPARγ haplodeficient
(PPARγ+/−) mice. A: VEGF in PACs. B: KDR in PACs. C: SDF-1 in PACs.
D: CXCR4 in PACs. Quantitative RT-PCR. EF2 serves as an internal control.
E: Percentage of CD45−KDR+Sca-1+ cells in bone marrow. F: Percentage
of CD45−KDR+Sca-1+ cells in blood. Multicolor FACS phenotyping.
Each bar represents mean + SEM. N = 5-6 (Figure S3 A-D), N = 5-9
(Figure S3 E-F).
Additional file 5: Figure S4. Expression of angiogenic genes in bone
marrow and gastrocnemius muscle of wild type (WT) or PPARγ
haplodeficient (PPARγ+/−) mice, untreated (control) or one day after
hind limb ischemia (HLI). A: VEGF in bone marrow. B: VEGF in muscle.
C: SDF-1 in bone marrow. D: SDF-1 in muscle. E: KDR in bone marrow.
F: KDR in muscle. G: CXCR4 in bone marrow. H: CXCR4 in muscle.
Quantitative RT-PCR. EF2 serves as an internal control. Each bar r
epresents mean + SEM. N = 5-6, *p < 0.05, **p < 0.01, ***p < 0.001
versus control.
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